| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Ratings for Arcellx (NASDAQ:ACLX) were provided by 8 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 6 | 2 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 0 | 0 | 0 |
| 2M Ago | 4 | 1 | 0 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $81.0, a high estimate of $87.00, and a low estimate of $70.00. This current average has decreased by 1.94% from the previous average price target of $82.60.
The analysis of recent analyst actions sheds light on the perception of Arcellx by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Asthika Goonewardene | Truist Securities | Maintains | Buy | $87.00 | $87.00 |
| Biren Amin | Piper Sandler | Announces | Overweight | $70.00 | - |
| Benjamin Burnett | Stifel | Raises | Buy | $83.00 | $82.00 |
| Cory Kasimov | Evercore ISI Group | Announces | Outperform | $85.00 | - |
| Emily Bodnar | HC Wainwright & Co. | Lowers | Buy | $80.00 | $82.00 |
| Gil Blum | Needham | Maintains | Buy | $81.00 | $81.00 |
| Gil Blum | Needham | Maintains | Buy | $81.00 | $81.00 |
| Gil Blum | Needham | Maintains | Buy | $81.00 | - |
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Arcellx's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Arcellx analyst ratings.
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases.
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Arcellx's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of 119.16%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Arcellx's net margin is impressive, surpassing industry averages. With a net margin of -18.34%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -1.47%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Arcellx's ROA stands out, surpassing industry averages. With an impressive ROA of -0.9%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.18, Arcellx adopts a prudent financial strategy, indicating a balanced approach to debt management.
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: ACLX
